1Cell.Ai Launches OncoIncytes, Revolutionizing Precision Oncology With Advanced Multi-Modal Data Integration

OneCell Diagnostics has announced the launch of OncoIncytes, a next-generation cancer diagnostic panel that represents a significant advancement in precision oncology. The company is also undergoing a rebranding and will now operate under the name 1Cell.Ai. This change marks its strategic shift from a genomics-based diagnostics company to a data science and artificial intelligence (AI)-powered leader in cancer diagnostics and research.

OncoIncytes is a comprehensive multi-modal platform that integrates multiple types of biological data, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) analyzed at single-cell resolution, RNA transcriptomics, and proteomics, which includes the analysis of 150 proteins at the single-cell level. This broad integration allows for an in-depth view of tumor biology and offers a powerful tool for both clinical and research applications.

The core of the OncoIncytes platform is a 1080 gene panel that utilizes advanced AI and machine learning models to provide high-resolution insights into cancer biology. This enables more informed clinical decision-making, particularly for pharmaceutical and biotech companies developing antibody-drug conjugates (ADCs). OncoIncytes can detect protein expression on the surface of cells—something that conventional liquid biopsy methods are often unable to capture—thereby offering critical support during early-stage clinical development of targeted therapies.

This new diagnostic technology has applications across several key areas, including cancer research, drug development, patient selection for clinical trials, and monitoring of therapy response. To facilitate adoption, 1Cell.Ai is offering sample collection kits that can be shipped directly to hospitals and clinical trial sites. Once the samples are collected, they are sent to the company’s laboratory in Foster City, California, which has recently received CLIA certification. The data from the samples is analyzed and the results are made available through 1Cell.Ai’s digital platform, iDiscover, ensuring accuracy and speed in reporting.

Mohan Uttarwar, CEO and co-founder of 1Cell.Ai., said in a statement, “By integrating true single cell level multi-omics data with ctDNA, OncoIncytes provides unparalleled information to oncologists that enhances critical clinical decisions. This approach offers unprecedented sensitivity and specificity to optimize clinical trial successes, particularly in early-stage research. For antibody-drug conjugate studies, this represents a unique way to select the most appropriate patients, and address one of the most significant challenges in translational research.”

He further added, “Our commitment to democratizing precision oncology through more accessible, actionable, and affordable diagnostic cancer testing remains stronger than ever. The rebranding to 1Cell.Ai reflects our expanded mission to revolutionize cancer care through artificial intelligence, moving beyond diagnostics to more comprehensive AI-powered precision oncology solutions.”

The 1080 gene panel has been thoroughly validated against other industry-standard next-generation sequencing (NGS) platforms, including Illumina’s TSO 500 and the FDA-cleared PGDx panel. This validation was conducted at Dr. Ravindra Kohle’s laboratory at Augusta University’s Medical College of Georgia, and the results demonstrated a 100 percent concordance between the different testing methodologies, confirming the reliability and accuracy of the OncoIncytes panel.

The launch of OncoIncytes and the transition to 1Cell.Ai follows the company’s recently completed and oversubscribed $16 million Series A funding round. In addition, the company has established a clinical advisory board comprised of global experts in oncology, chaired by Nobel Laureate Dr. James Rothman. These developments position 1Cell.Ai at the forefront of innovation in cancer diagnostics, combining deep scientific expertise with cutting-edge data science to deliver meaningful advancements in cancer care.